KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Halozyme Therapeutics (HALO) Net Cash Flow (2016 - 2025)

Halozyme Therapeutics (HALO) has disclosed Net Cash Flow for 16 consecutive years, with -$283.2 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow fell 636.31% to -$283.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $20.6 million through Dec 2025, up 916.31% year-over-year, with the annual reading at $20.6 million for FY2025, 916.31% up from the prior year.
  • Net Cash Flow for Q4 2025 was -$283.2 million at Halozyme Therapeutics, down from $357.8 million in the prior quarter.
  • The five-year high for Net Cash Flow was $357.8 million in Q3 2025, with the low at -$373.0 million in Q4 2021.
  • Average Net Cash Flow over 5 years is -$589100.0, with a median of $11.2 million recorded in 2022.
  • The sharpest move saw Net Cash Flow skyrocketed 2390.17% in 2021, then tumbled 15489.59% in 2023.
  • Over 5 years, Net Cash Flow stood at -$373.0 million in 2021, then soared by 123.34% to $87.0 million in 2022, then crashed by 279.07% to -$155.9 million in 2023, then soared by 75.32% to -$38.5 million in 2024, then plummeted by 636.31% to -$283.2 million in 2025.
  • According to Business Quant data, Net Cash Flow over the past three periods came in at -$283.2 million, $357.8 million, and -$114.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.